UARK 2009-32 Compassionate Use Study of Carfilzomib

Inclusion Criteria: * Participants must have histologically documented multiple myeloma which is relapsing or resistant after stem cell transplantation, or when other conventional therapies have failed or are contraindicated * Serum creatinine \< 3.0 mg/dL OR calculated creatinine clearance \>15 mL/min calculated or measured clearance is ≥15 mL/min * ANC \> 1000/mm3 (may be supported with growth factors) * Platelet count \> 30,000/mm3 (may receive transfusion) * Female participant of child-bearing potential has agreed to use dual methods of contraception for the duration of the study * Male participant has agreed to use a barrier method of contraception if sexually active with a female of child-bearing potential * Patients must have signed and IRB-approved written informed consent form and demonstrate willingness to meet follow-up schedule and study procedure obligations Exclusion Criteria: * Active infection requiring systemic treatment * Requires concomitant use of approved or investigative anticancer therapeutic treatment with activity against multiple myeloma, other than dexamethasone * Concomitant use of other investigative agents (e.g., antibiotics or antiemetics) * Pregnant or breast-feeding